Biomarkers and Personalized Therapies in Pancreatic Cancer

Guest Editor:

Dr. Tracy Putoczki
Personalized Oncology Division,
The Walter and Eliza Hall
Institute of Medical Research

Deadline for manuscript submissions:
closed (31 October 2019)

Message from the Guest Editor

Pancreatic cancer is the most lethal of all solid malignancies, with a significant rise in deaths predicted by 2020. Currently, standard-of-care chemotherapeutics remain the best treatment option for patients.

In this Special Issue, emerging opportunities to personalise a patient's treatment journey will be discussed. These include new strategies to detect the cancer and monitor a patient's response by a blood test, our evolving understanding of molecular profiles and tumour sub-types, a new understanding of the complex role the tumour microenvironment plays in treatment responses, selection of appropriate patients for targeted therapies, and opportunities to better segregate patients in design clinical trials.

mdpi.com/si/21820

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us